X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (86) 86
index medicus (76) 76
female (57) 57
hematology (55) 55
middle aged (55) 55
oncology (54) 54
male (52) 52
aged (51) 51
adult (42) 42
aged, 80 and over (36) 36
treatment outcome (32) 32
acute myeloid-leukemia (29) 29
article (26) 26
leukemia, myeloid, acute - drug therapy (26) 26
prognosis (26) 26
cancer (24) 24
leukemia (18) 18
myelodysplastic syndromes (18) 18
therapy (18) 18
acute myeloid leukemia (17) 17
antineoplastic combined chemotherapy protocols - therapeutic use (17) 17
acute myelogenous leukemia (16) 16
myelodysplastic syndromes - drug therapy (16) 16
chemotherapy (15) 15
survival rate (15) 15
abridged index medicus (14) 14
azacitidine - analogs & derivatives (14) 14
leukemia, myeloid, acute - mortality (14) 14
leukemia, myeloid, acute - pathology (14) 14
remission induction (14) 14
disease-free survival (13) 13
dose-response relationship, drug (13) 13
leukemia, myeloid, acute - genetics (13) 13
antineoplastic agents - therapeutic use (12) 12
young adult (12) 12
aml (11) 11
azacitidine - administration & dosage (11) 11
care and treatment (11) 11
cytarabine - administration & dosage (11) 11
decitabine (11) 11
diagnosis (11) 11
hematology, oncology and palliative medicine (11) 11
hemic and lymphatic diseases (11) 11
myelodysplastic syndrome (11) 11
patients (11) 11
research (11) 11
antineoplastic agents - adverse effects (10) 10
azacitidine (10) 10
cells (10) 10
leukemia, myeloid, acute - diagnosis (10) 10
leukemia, myeloid, acute - therapy (10) 10
mutation (10) 10
myelodysplastic syndromes - mortality (10) 10
older patients (10) 10
recurrence (10) 10
risk factors (10) 10
survival (10) 10
adolescent (9) 9
animals (9) 9
cytarabine (9) 9
kaplan-meier estimate (9) 9
mds (9) 9
retrospective studies (9) 9
analysis (8) 8
clinical trials (8) 8
clinical trials and observations (8) 8
drug administration schedule (8) 8
follow-up studies (8) 8
risk (8) 8
risk myelodysplastic syndrome (8) 8
transplantation (8) 8
acute disease (7) 7
antimetabolites, antineoplastic - therapeutic use (7) 7
antineoplastic agents - administration & dosage (7) 7
azacitidine - therapeutic use (7) 7
disease progression (7) 7
drug therapy (7) 7
myelodysplastic syndromes - pathology (7) 7
relapse (7) 7
scoring system (7) 7
survival analysis (7) 7
acute promyelocytic leukemia (6) 6
age (6) 6
bone marrow (6) 6
clinical trials as topic (6) 6
drug resistance, neoplasm (6) 6
elderly-patients (6) 6
health aspects (6) 6
hematopoietic stem cell transplantation (6) 6
induction (6) 6
maximum tolerated dose (6) 6
medical research (6) 6
mortality (6) 6
mutations (6) 6
remission (6) 6
stem cells (6) 6
trial (6) 6
tumors (6) 6
bone-marrow (5) 5
cell line, tumor (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Clinical Advances in Hematology and Oncology, ISSN 1543-0790, 05/2018, Volume 16, Issue 5, pp. 322 - 325
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Suppl_1, pp. 4374 - 4374
Abstract Background: Only a minority of patients diagnosed with myelodysplastic syndromes (MDS) enroll in interventional clinical trials, which impedes... 
Journal Article
Best Practice & Research Clinical Haematology, ISSN 1521-6926, 06/2019, Volume 32, Issue 2, pp. 177 - 185
Acute Myeloid Leukemia, the most common form of acute leukemia in adults, is an aggressive hematopoietic stem cell malignancy that is associated with... 
ARCH | CHIP | Acute myeloid leukemia | Myelodysplastic syndrome | Clonal hematopoiesis | SHWACHMAN-DIAMOND SYNDROME | TP53 MUTATIONS | SOMATIC MUTATIONS | EVOLUTION | GENE | FANCONI-ANEMIA PATIENTS | MALIGNANCIES | PROGNOSTIC RELEVANCE | HEMATOLOGY | BONE-MARROW FAILURE | Chemotherapy | Mortality | Hematopoietic stem cells | Cancer
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 1433 - 1433
Abstract Background: CPX-351 (Vyxeos) is a liposomal combination of daunorubicin and cytarabine that was FDA approved in 2017 for treatment of adults with... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 2172 - 2172
Abstract Introduction: Mutations at diagnosis in acute myeloid leukemia (AML) patients have prognostic implications. For AML patients undergoing allogeneic... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 4038 - 4038
Abstract Introduction: Midostaurin was the first multikinase inhibitor approved in combination with daunorubicin and cytarabine induction and high-dose... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 1434 - 1434
Abstract Background: CPX-351 (Vyxeos®) is a dual-drug liposomal encapsulation of cytarabine and daunorubicin at a synergistic ratio. In a large randomized,... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 1455 - 1455
Abstract Background: AMV564 is a novel bivalent, bispecific (2x2) CD33/CD3 targeted immunotherapy that binds both CD33 and the invariant CD3ε on T-cell... 
Journal Article
Molecular Therapy, ISSN 1525-0016, 05/2016, Volume 24, pp. S157 - S158
Journal Article
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 793 - 793
Abstract Background Patients (pts) with myelodysplastic syndromes (MDS) have heterogeneous outcomes that can range from months for some pts to decades for... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 2741 - 2741
Abstract Background: Approval of CPX-351 has changed the treatment landscape for therapy-related acute myeloid leukemia (t-AML) or AML with... 
Journal Article
Cold Spring Harbor perspectives in biology, 04/2019
Cancer is often associated with alterations in the chaperome, a collection of chaperones, cochaperones, and other cofactors. Changes in the expression levels... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 4391 - 4391
Abstract Background: Allogeneic stem cell transplant remains the only curative modality for myelodysplastic syndrome (MDS), yet there is significant... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 284 - 284
Abstract BACKGROUND: The median age for diagnosis of acute myeloid leukemia (AML) is 68 years. Elderly patients are often ineligible for intensive chemotherapy... 
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.